NEWS
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides announced a significant advancement in its lead antiviral agent, NV-387. This drug, designed for broad-spectrum antiviral treatment, has shown prolonged blood concentration levels in non-human primate models, indicating the potential for infrequent dosing. NV-387's unique polymeric design helps sustain drug levels, making it effective for moderate to severe viral infections like RSV, COVID, and influenza. The drug demonstrated superior performance over existing antiviral drugs in preclinical studies and is expected to proceed to Phase II clinical trials for RSV.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1066Followers
68Following
7336Visitors
Follow